AstraZeneca’s Tagrisso with the addition of pemetrexed and platinum-based chemotherapy has been approved in China for the first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, whose tumours have exon 19 deletions or exon 21 mutations, the company announced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- UK Stocks: AstraZeneca’s (AZN) Imfinzi Disappoints in Advanced Lung Cancer Trial
- AstraZeneca reports Truqap plus Faslodex approved in EU for breast cancer
- AstraZeneca reports CAPItello-290 Phase 3 trial did not meet primary endpoints
- AstraZeneca: IMFINZI +chemo gets approval for endometrial cancer with dMMR
- AstraZeneca reports Imfinzi plus chemo approved for endometrial cancer in U.S.